ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marruchella, A
Right arrow Articles by Chiodera, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marruchella, A
Right arrow Articles by Chiodera, P.
Eur Respir J 1998; 11: 504-506
Copyright © ERS Journals Ltd 1998

Case Studies

Diffuse alveolar damage in a patient treated with gemcitabine

A Marruchella, G Fiorenzano, A Merizzi, G Rossi, and PL Chiodera

We present a case of diffuse alveolar damage (DAD) that occurred in a male aged 68 yrs treated with gemcitabine, a novel antineoplastic agent, that was given for hepatic relapse of a previously resected non-small cell lung cancer. The patient developed acute respiratory failure after the sixth drug dose, and died 4 days after admission. Autopsy revealed a pattern of DAD. No evidence of infection or other specific aetiologies could be found. To our knowledge, only three cases of pulmonary toxicity resulting from treatment with gemcitabine have been published; two of them were fatal and postmortem examination revealed a pattern consistent with acute respiratory distress syndrome. A careful survey may determine the incidence of pulmonary toxicity of this new drug in the future.


This article has been cited by other articles:


Home page
 Anticancer ResHome page
A. G. CHARPIDOU, I. GKIOZOS, S. TSIMPOUKIS, D. APOSTOLAKI, K. D. DILANA, E. M. KARAPANAGIOTOU, and K. N. SYRIGOS
Therapy-induced Toxicity of the Lungs: An Overview
Anticancer Res, February 1, 2009; 29(2): 631 - 639.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Ko, S. Lee, and A. Goodman
Gemcitabine Pulmonary Toxicity in Ovarian Cancer
Oncologist, July 1, 2008; 13(7): 807 - 811.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. Vahid and P. E. Marik
Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors*
Chest, February 1, 2008; 133(2): 528 - 538.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I. Dimopoulou, A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos
Pulmonary toxicity from novel antineoplastic agents
Ann. Onc., March 1, 2006; 17(3): 372 - 379.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Li, B. Juliar, C. Yiannoutsos, R. Ansari, E. Fox, M. J. Fisch, L. H. Einhorn, and C. J. Sweeney
Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study
J. Clin. Oncol., February 20, 2005; 23(6): 1185 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 Chest MeetingHome page
O. Gajic
Gemcitabine Pulmonary Toxicity
Chest Meeting Abstracts, October 1, 2003; 124(4): 244S - 245.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Briasoulis and N. Pavlidis
Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy
Oncologist, April 1, 2001; 6(2): 153 - 161.
[Abstract] [Full Text]

Home page
 JCOHome page
E. C. Attar, T. Ervin, M. Janicek, A. Deykin, and J. Godleski
Side Effects of Chemotherapy
J. Clin. Oncol., February 1, 2000; 18(3): 697 - 697.
[Full Text] [PDF]

Home page
 ChestHome page
A. Marruchella, M. Tondini, N. Vander Els, and V. Miller
Gemcitabine Toxicity
Chest, November 1, 1999; 116(5): 1491 - 1491.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the European Respiratory Society.